Rationale for Correct Answer

The correct answer is: Entrectinib and larotrectinib

Entrectinib and larotrectinib inhibit the neuroreceptor tyrosine kinases NTRK1, NTRK2, and NTRK3, proteins that are involved in the development and maintenance of the nervous system.1 Common adverse events in clinical trials of these agents included dizziness, cognitive impairment, mood disorders, sleep disturbance, headache, dysgeusia, dysesthesia, and peripheral sensory neuropathy.2,3 Capmatinib and tepotinib (MET targeted agents), pralsetinib and selpercatinib (RET targeted agents), and adagrasib and sotorasib (KRAS targeted agents) were not associated with high rates of CNS adverse events.4

1. Harada G et al. Nat Rev Clin Oncol. 2023;20:229-249.
2. VITRAKVI®. Prescribing information. Bayer; March 2021.
3. ROZLYTREK®. Prescribing information. Genentech; Nov. 2021.
4. U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications . Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm